Topiramate

NDC 69680-180 · Vitruvias Therapeutics, Inc.

Generic nameTopiramate

Dosage formCAPSULE, EXTENDED RELEASE

RouteORAL

Active ingredient(s)TOPIRAMATE

Strength150 mg/1

Pharmacologic classCytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]

Marketing categoryANDA

Packages

69680-180-30 — 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (69680-180-30)

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

69097-123 — Topiramate, 69097-124 — Topiramate, 69097-125 — Topiramate, 69097-816 — Topiramate, 69097-817 — Topiramate, 69097-818 — Topiramate, 69097-819 — Topiramate, 69680-177 — Topiramate, 69680-178 — Topiramate, 69680-179 — Topiramate, 69680-181 — Topiramate, 70518-0233 — topiramate, 70518-0625 — Topiramate, 70518-1180 — topiramate, 70518-1196 — Topiramate, 70518-1718 — topiramate, 70518-1937 — topiramate, 70518-1953 — topiramate, 70518-2001 — topiramate, 70518-2104 — topiramate, +289 more

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels